Newly diagnosed patients with celiac disease were found to be at risk of metabolic syndrome and hepatic steatosis upon adopting a gluten-free diet. An in-depth nutritional assessment is recommended at diagnosis and during follow-up.
New drugs on the research horizon could spare people with celiac the pain of accidentally eating pizza or pasta. Even with the best intentions, living gluten-free is much easier said than done. It was almost impossible to tell which packaged “gluten-free” foods lived up to their claims until late last year when the U.S. Food […]
The Kansas Wheat Commission is spending $200,000 to identify everything in wheat’s DNA sequences that can trigger a reaction in people suffering from celiac disease, an autoimmune disorder in which eating even tiny amounts of gluten can damage the small intestine.
On March 30-31st, 2015, Celiac Disease Foundation Chief Executive Officer, Marilyn G. Geller, attended the FDA Public Workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3) near Washington, D.C. This landmark conference addressed endpoints and outcome measures for trials for products intended to treat celiac disease and Irritable Bowel Disease. The second day […]
Those who have the standard clinical symptoms of celiac disease, such as sensitivity to gluten, irritability, abdominal pain, or a positive blood test, may undergo an endoscopy to confirm their diagnosis. During the procedure, doctors take samples of tissue (a biopsy) from the small intestine to see if there is damage or flattening of villi. Under a microscope, a […]
Celiac Disease Foundation is pleased to announce our participation in the Autoimmune Research Network, known as ARNet. ARNet is a network of autoimmune disease advocacy organizations that will foster research into celiac disease and related autoimmune conditions. In consonance with CDF’s Strategic Plan to increase national awareness of the ramifications of undiagnosed celiac disease, the first goal of […]
Celiac Disease Foundation is pleased to announce the March 30-31, 2015, U.S. Food and Drug Administration (FDA) public workshop on Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT3). This scientific meeting will address endpoints and outcome measures for clinical trials for products intended to treat adult and/or pediatric celiac disease and inflammatory bowel disease.
Currently, the typical treatment for a patient diagnosed with celiac disease is a strict gluten-free diet for life. Future therapies currently in the pipeline hope to make living with celiac disease less of a burden.
For people with celiac disease, vaccinations tend to work just as effectively as they do for the general population with one notable exception: hepatitis B. Celiac disease testing is recommended for non-responders to the hepatitis B vaccine who are not already diagnosed.
Celiac Disease (CD), a genetic condition affecting 1% of the population, is somewhat unique among autoimmune conditions in that it has an effective treatment in the gluten-free diet. However, the diet can be difficult to follow; a significant proportion of CD patients do not respond to the diet with the expected intestinal healing, typically due […]